Methods of Solving Rapid Binding Target-mediated Drug Disposition Model for Two Drugs Competing for the Same Receptor

Overview

Journal J Pharmacokinet Pharmacodyn

Publisher Springer

Specialty Pharmacology

Date 2012 Aug 29

PMID 22926955

Citations 21

Authors

Xiaoyu Yan

Yang Chen

Wojciech Krzyzanski

Affiliations

Soon will be listed here.

Abstract

The target-mediated drug disposition (TMDD) model has been adopted to describe pharmacokinetics for two drugs competing for the same receptor. A rapid binding assumption introduces total receptor and total drug concentrations while free drug concentrations C (A) and C (B) are calculated from the equilibrium (Gaddum) equations. The Gaddum equations are polynomials in C (A) and C (B) of second degree that have explicit solutions involving complex numbers. The aim of this study was to develop numerical methods to solve the rapid binding TMDD model for two drugs competing for the same receptor that can be implemented in pharmacokinetic software. Algebra, calculus, and computer simulations were used to develop algorithms and investigate properties of solutions to the TMDD model with two drugs competitively binding to the same receptor. A general rapid binding approximation of the TMDD model for two drugs competing for the same receptor has been proposed. The explicit solutions to the equilibrium equations employ complex numbers, which cannot be easily solved by pharmacokinetic software. Numerical bisection algorithm and differential representation were developed to solve the system instead of obtaining an explicit solution. The numerical solutions were validated by MATLAB 7.2 solver for polynomial roots. The applicability of these algorithms was demonstrated by simulating concentration-time profiles resulting from exogenous and endogenous IgG competing for the neonatal Fc receptor (FcRn), and darbepoetin competing with endogenous erythropoietin for the erythropoietin receptor. These models were implemented in ADAPT 5 and Phoenix WinNonlin 6.0, respectively.

Citing Articles

General quasi-equilibrium multivalent binding model to study diverse and complex drug-receptor interactions of biologics.

Ng C, Bauer R J Pharmacokinet Pharmacodyn. 2024; 51(6):841-857.

PMID: 39153154 DOI: 10.1007/s10928-024-09936-5.

Optimizing Clinical Translation of Bispecific T-cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model.

Liao X, Qi T, Zhou J, Liu C, Cao Y Clin Pharmacol Ther. 2024; 116(2):415-425.

PMID: 38751031 PMC: 11251864. DOI: 10.1002/cpt.3302.

Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance.

Liu C, Zhou J, Kudlacek S, Qi T, Dunlap T, Cao Y Elife. 2023; 12.

PMID: 37490053 PMC: 10368424. DOI: 10.7554/eLife.83659.

The quest for balance between capturing data and model complexity: A quantitative clinical pharmacology approach applied to monoclonal antibodies.

Pressly M, Peletier L, Zheng S, Sharma V, Lien Y, Wang W CPT Pharmacometrics Syst Pharmacol. 2023; 12(5):639-655.

PMID: 36752286 PMC: 10196441. DOI: 10.1002/psp4.12927.

Algorithmic multiscale analysis for the FcRn mediated regulation of antibody PK in human.

Patsatzis D, Wu S, Shah D, Goussis D Sci Rep. 2022; 12(1):6208.

PMID: 35418134 PMC: 9008124. DOI: 10.1038/s41598-022-09846-x.

References

Wang Y, Krzyzanski W, Doshi S, Xiao J, Perez-Ruixo J, Chow A . Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 2010; 12(4):729-40. PMC: 2976980. DOI: 10.1208/s12248-010-9234-9. View

Mager D, Krzyzanski W . Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005; 22(10):1589-96. DOI: 10.1007/s11095-005-6650-0. View

Roopenian D, Akilesh S . FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7(9):715-25. DOI: 10.1038/nri2155. View

Vaccaro C, Zhou J, Ober R, Ward E . Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005; 23(10):1283-8. DOI: 10.1038/nbt1143. View

Hayes S, Ouellet D, Zhang J, Wire M, Gibiansky E . Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol. 2010; 51(10):1403-17. DOI: 10.1177/0091270010383019. View

Hansen R, Balthasar J . Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci. 2003; 92(6):1206-15. DOI: 10.1002/jps.10364. View

Woo S, Krzyzanski W, Jusko W . Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn. 2007; 34(6):849-68. DOI: 10.1007/s10928-007-9074-0. View

Gibiansky L, Gibiansky E, Kakkar T, Ma P . Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008; 35(5):573-91. DOI: 10.1007/s10928-008-9102-8. View

Stead R, Lambert J, Wessels D, Iwashita J, Leuther K, Woodburn K . Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006; 108(6):1830-4. DOI: 10.1182/blood-2006-04-015818. View

10.

Levy G . Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther. 1994; 56(4):356-8. DOI: 10.1038/clpt.1994.149. View

11.

Egrie J, Browne J . Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 Suppl 1:3-10. PMC: 2363897. DOI: 10.1054/bjoc.2001.1746. View

12.

Yan X, Mager D, Krzyzanski W . Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2009; 37(1):25-47. PMC: 3157300. DOI: 10.1007/s10928-009-9142-8. View

13.

Doshi S, Chow A, Perez Ruixo J . Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. J Clin Pharmacol. 2010; 50(9 Suppl):75S-90S. DOI: 10.1177/0091270010377201. View

14.

Mager D . Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006; 72(1):1-10. DOI: 10.1016/j.bcp.2005.12.041. View

15.

Gross A, Lodish H . Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem. 2005; 281(4):2024-32. DOI: 10.1074/jbc.M510493200. View

16.

Wang B, Nichol J, Sullivan J . Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004; 76(6):628-38. DOI: 10.1016/j.clpt.2004.08.010. View

17.

Macdougall I . CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005; 4(6):436-40. View

18.

Deng R, Loyet K, Lien S, Iyer S, DeForge L, Theil F . Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos. 2010; 38(4):600-5. DOI: 10.1124/dmd.109.031310. View

19.

Mager D, Jusko W . General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2002; 28(6):507-32. DOI: 10.1023/a:1014414520282. View

20.

Kaushansky K . Lineage-specific hematopoietic growth factors. N Engl J Med. 2006; 354(19):2034-45. DOI: 10.1056/NEJMra052706. View